SEOUL, Dec 14 -- British-Swedish pharmaceutical giant AstraZeneca said Tuesday that Samsung Biologics Co, the biotech arm of Samsung Group, will manufacture its antibody combination against COVID-19, reported Yonhap news agency.
Under an agreement valued at approximately US$380 million (US$1=RM4.21), Samsung Biologics will manufacture AZD7442 - AstraZeneca's combination of two long-acting antibodies in development for the potential treatment of COVID-19 - at its plant in Songdo, Incheon, 40 kilometres west of Seoul.
The deal represents a hike from a long-term supply agreement valued at US$331 million signed between the two firms in September.
The AZD7442 is the first antibody treatment against COVID-19 that has won an Emergency Use Authorisation from the United States Food and Drug Administration. It has also won approval from drug authorities in other countries, including France and Italy.
The deal includes Samsung Biologics manufacturing AstraZeneca's oncology drug Imfinzi at its plant starting next year.
Imfinzi has won approval in many countries, including South Korea, for the treatment of lung cancer. The drug is currently under study for the treatment of other cancers.
-- BERNAMA
BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.
Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial
